Ultimovacs - Staying alive with UV1 in NIPU and INTIUM
Ultimovacs’ Q323 update recapped an active period, including the recently announced positive data from the NIPU trial evaluating lead cancer vaccine UV1 for the treatment of malignant pleural mesothelioma (MPM). As previously noted, the key observation was reduced risk of death by 27% with UV1 treatment compared to control. Although overall survival (OS) is the secondary endpoint of the NIPU Phase II trial, OS is regarded as the gold standard of cancer treatment endpoints and a critical consideration in MPM, an aggressive type of cancer with a high mortality rate and few therapeutic options. We believe the next key catalyst for Ultimovacs will be results from the INITIUM trial in malignant melanoma, which, after an agreement with regulatory authorities to enable an earlier analysis, are now confirmed for H124. At end-Q323, the company had net cash of NOK300.3m, which management estimates provides a cash runway to H224 and through topline readouts from the INITIUM and FOCUS trials.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.